Local recurrence and local control of non‐metastatic osteosarcoma of the extremities: A 27‐year experience in a single institution
- 18 June 2007
- journal article
- research article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 96 (2) , 118-123
- https://doi.org/10.1002/jso.20628
Abstract
Background Indications and contraindications for limb salvage versus amputation for local treatment of osteosarcoma of the extremity are still controversial. Patients and Methods Patients (1,126) with non-metastatic osteosarcoma of the extremity, treated in a single institution between 1972 and 1999 with different protocols of adjuvant and neoadjuvant chemotherapy were evaluated to establish factors that could influence local recurrence (LR) and outcome. Results The 5-year event-free survival and overall survival were 55% and 66%. At a follow-up ranging between 5.5 and 32.5 years (mean18.6 years) of the 1,126 evaluated patients, 607 (54%) remained continuously disease-free and 519 relapsed. LR developed in 61 patients (5.4%) after a median time of 2.3 years (0.2–17). For this group of patients the 5-year post-relapse event-free survival and overall survival from the last relapse were, respectively, 11.4% and 16.4%. At the multivariate analyses only surgical margins and histologic response to preoperative treatment resulted to be independent prognostic factors for LR. Conclusion Considering the risk of LR after surgery with inadequate surgical margins and poor prognosis of LR in osteosarcoma, limb salvage procedures should be performed only when adequate margins surgical margins can be achieved. In case of inadequate margins, an immediate amputation should be considered. J. Surg. Oncol. 2007;96:118–123.Keywords
This publication has 26 references indexed in Scilit:
- Management and outcome after local recurrence of osteosarcomaEuropean Journal Of Cancer, 2005
- Outcome after local recurrence of osteosarcomaCancer, 2004
- Surgical outcomes in osteosarcomaThe Journal of Bone and Joint Surgery. British volume, 2002
- High Dose Ifosfamide in Combination with High Dose Methotrexate, Adriamycin and Cisplatin in the Neoadjuvant Treatment of Extremity Osteosarcoma: Preliminary Results of an Italian Sarcoma Group/Scandinavian Sarcoma Group Pilot StudyJournal of Chemotherapy, 2002
- Osteosarcoma of the limbThe Journal of Bone and Joint Surgery. British volume, 2002
- The effect of local recurrence on survival in resected osteosarcomaEuropean Journal Of Cancer, 2001
- Nonmetastatic Osteosarcoma of the Extremity: Results of a Neoadjuvant Chemotherapy Protocol (IOR/OS-3) with High-dose Methotrexate, Intraarterial or Intravenous Cisplatin, Doxorubicin, and Salvage Chemotherapy Based on Histologic Tumor ResponseTumori Journal, 1999
- Limb Salvage and Outcome of OsteosarcomaPublished by Wolters Kluwer Health ,1999
- Adriamycin-methotrexate high dose versus adriamycin-methotrexate moderate dose as adjuvant chemotherapy for osteosarcoma of the extremities: a randomized studyEuropean Journal of Cancer and Clinical Oncology, 1986
- A System for the Surgical Staging of Musculoskeletal SarcomaClinical Orthopaedics and Related Research, 1980